RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      KCI등재 SCOPUS SCIE

      Enhancement of antitumor effect of radiotherapy via combination with Au@SiO2 nanoparticles targeted to tumor-associated macrophages

      한글로보기

      https://www.riss.kr/link?id=A106838801

      • 0

        상세조회
      • 0

        다운로드
      서지정보 열기
      • 내보내기
      • 내책장담기
      • 공유하기
      • 오류접수

      부가정보

      다국어 초록 (Multilingual Abstract)

      Tumor-associated macrophages (TAMs) exhibit the M2 phenotype and serve as critical tumor-promotingimmune cells in the tumor microenvironment. As TAMs are an important target, we examined the effectof gold nanoparticles (AuNPs) with radiotherapy (RT) on M2 TAMs in tumors. We synthesized CD163antibody-conjugated, silica-coated AuNPs (CD163-GNPs) that were specifically recognized by M2 TAMs.
      Bone marrow-derived macrophages and Raw 264.7 macrophages were polarized into M1 and M2phenotypes. The effect of CD163-GNPs combined with RT was evaluated in a CT26 syngeneic mousemodel (BALB/c mice). Immunostaining,flow cytometry, microscopic analyses, enzyme-linkedimmunosorbent assay, quantitative real-time polymerase chain reaction (qRT-PCR), and tumor growthdelay assay were performed following irradiation combined with CD163-GNP treatment. We observedselective phagocytosis of CD163-GNPs by Raw 264.7 macrophages following M1/M2 polarization.
      Immunostaining analyses revealed higher numbers of CD163-GNPs taken up by M2 macrophages thanM0 or M1 type. CD163-GNPs combined with RT significantly reduced tumor growth in the CT26syngeneic mouse model. Macrophages subjected to the combination treatment showed increasedexpression of M1 markers. The depletion of M2 TAMs in tumors upon combination treatment withCD163-GNPs enhances the efficiency of RT.
      번역하기

      Tumor-associated macrophages (TAMs) exhibit the M2 phenotype and serve as critical tumor-promotingimmune cells in the tumor microenvironment. As TAMs are an important target, we examined the effectof gold nanoparticles (AuNPs) with radiotherapy (RT) o...

      Tumor-associated macrophages (TAMs) exhibit the M2 phenotype and serve as critical tumor-promotingimmune cells in the tumor microenvironment. As TAMs are an important target, we examined the effectof gold nanoparticles (AuNPs) with radiotherapy (RT) on M2 TAMs in tumors. We synthesized CD163antibody-conjugated, silica-coated AuNPs (CD163-GNPs) that were specifically recognized by M2 TAMs.
      Bone marrow-derived macrophages and Raw 264.7 macrophages were polarized into M1 and M2phenotypes. The effect of CD163-GNPs combined with RT was evaluated in a CT26 syngeneic mousemodel (BALB/c mice). Immunostaining,flow cytometry, microscopic analyses, enzyme-linkedimmunosorbent assay, quantitative real-time polymerase chain reaction (qRT-PCR), and tumor growthdelay assay were performed following irradiation combined with CD163-GNP treatment. We observedselective phagocytosis of CD163-GNPs by Raw 264.7 macrophages following M1/M2 polarization.
      Immunostaining analyses revealed higher numbers of CD163-GNPs taken up by M2 macrophages thanM0 or M1 type. CD163-GNPs combined with RT significantly reduced tumor growth in the CT26syngeneic mouse model. Macrophages subjected to the combination treatment showed increasedexpression of M1 markers. The depletion of M2 TAMs in tumors upon combination treatment withCD163-GNPs enhances the efficiency of RT.

      더보기

      참고문헌 (Reference)

      1 Y. Wang, 9 : 185-, 2018

      2 L. Su, 11 : 4191-, 2015

      3 A. Teresa Pinto, 6 : 18765-, 2016

      4 X. Miao, 18 : 2017

      5 J. W. Pollard, 4 : 71-, 2004

      6 A. P. Cardoso, 33 : 2123-, 2014

      7 A. Mantovani, 25 : 677-, 2004

      8 A. P. Cardoso, 15 : 456-, 2015

      9 S. Vinogradov, 9 : 695-, 2014

      10 S. H. Cho, 54 : 4889-, 2009

      1 Y. Wang, 9 : 185-, 2018

      2 L. Su, 11 : 4191-, 2015

      3 A. Teresa Pinto, 6 : 18765-, 2016

      4 X. Miao, 18 : 2017

      5 J. W. Pollard, 4 : 71-, 2004

      6 A. P. Cardoso, 33 : 2123-, 2014

      7 A. Mantovani, 25 : 677-, 2004

      8 A. P. Cardoso, 15 : 456-, 2015

      9 S. Vinogradov, 9 : 695-, 2014

      10 S. H. Cho, 54 : 4889-, 2009

      11 J. Xu, 73 : 2782-, 2013

      12 J. W. Yoo, 16 : 2298-, 2010

      13 A. Sica, 42 : 717-, 2006

      14 P. Allavena, 167 : 195-, 2012

      15 L. Yang, 10 : 58-, 2017

      16 N. G. Bastus, 27 : 11098-, 2011

      17 G. Solinas, 86 : 1065-, 2009

      18 D. I. Gabrilovich, 12 : 253-, 2012

      19 B. Ruffell, 33 : 119-, 2012

      20 C. S. Chiang, 2 : 89-, 2012

      21 A. Weigert, 19 : 95-, 2008

      22 F. O. Martinez, 27 : 451-, 2009

      23 T. Lu, 121 : 4015-, 2011

      24 X. Bao, 96 : 2016

      25 R. Pal, 38 : 332-, 2016

      26 D. Hong, 7 : 2015

      27 K. Binnemars-Postma, 18 : 2017

      28 A. P. Cardoso, 23 : 157-, 2015

      29 A. Sica, 72 : 4111-, 2015

      30 F. Y. McWhorter, 72 : 1303-, 2015

      31 A. Sica, 122 : 787-, 2012

      32 J. Veeraraghavan, 286 : 21588-, 2011

      33 F. Kratochvill, 12 : 1902-, 2015

      34 S. Sathishkumar, 1 : 141-, 2002

      35 A. K. Fuchs, 85 : 78-, 2016

      36 A. Laskar, 441 : 737-, 2013

      37 김미선, "Gold nanoparticles enhance anti-tumor effect of radiotherapy to hypoxic tumor" 대한방사선종양학회 34 (34): 230-238, 2016

      더보기

      분석정보

      View

      상세정보조회

      0

      Usage

      원문다운로드

      0

      대출신청

      0

      복사신청

      0

      EDDS신청

      0

      동일 주제 내 활용도 TOP

      더보기

      주제

      연도별 연구동향

      연도별 활용동향

      연관논문

      연구자 네트워크맵

      공동연구자 (7)

      유사연구자 (20) 활용도상위20명

      인용정보 인용지수 설명보기

      학술지 이력

      학술지 이력
      연월일 이력구분 이력상세 등재구분
      2023 평가예정 해외DB학술지평가 신청대상 (해외등재 학술지 평가)
      2020-01-01 평가 등재학술지 유지 (해외등재 학술지 평가) KCI등재
      2011-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2009-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2007-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2004-01-01 평가 등재학술지 선정 (등재후보2차) KCI등재
      2003-01-01 평가 등재후보 1차 PASS (등재후보1차) KCI등재후보
      2001-07-01 평가 등재후보학술지 선정 (신규평가) KCI등재후보
      더보기

      학술지 인용정보

      학술지 인용정보
      기준연도 WOS-KCI 통합IF(2년) KCIF(2년) KCIF(3년)
      2016 3.4 0.75 2.84
      KCIF(4년) KCIF(5년) 중심성지수(3년) 즉시성지수
      2.39 2.24 0.397 0.56
      더보기

      이 자료와 함께 이용한 RISS 자료

      나만을 위한 추천자료

      해외이동버튼